Chemours (NYSE:CC) Cut to “Strong Sell” at Zacks Research

Chemours (NYSE:CC) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Wednesday, Zacks reports.

Several other equities analysts have also recently weighed in on CC. JPMorgan Chase & Co. reduced their price target on Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 13th. The Goldman Sachs Group reissued a “neutral” rating and set a $16.00 price objective on shares of Chemours in a report on Friday, October 9th. Barclays began coverage on Chemours in a research note on Monday, October 12th. They issued an “equal weight” rating and a $16.00 target price for the company. Morgan Stanley set a $18.00 target price on Chemours in a report on Monday, August 10th. Finally, Mizuho cut Chemours from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $18.00 to $15.00 in a research report on Wednesday, October 14th. Three equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Chemours has an average rating of “Hold” and a consensus target price of $17.45.

Chemours Stock Performance

Shares of CC stock opened at $12.77 on Wednesday. The stock has a market capitalization of $1.92 billion, a P/E ratio of -12.51 and a beta of 1.47. The company has a current ratio of 1.81, a quick ratio of 0.88 and a debt-to-equity ratio of 24.25. The firm’s 50 day moving average is $14.02 and its 200 day moving average is $18.23. Chemours has a 12 month low of $10.44 and a 12 month high of $28.67.

Chemours (NYSE:CC) last released its quarterly earnings data on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). Chemours had a negative net margin of 2.64% and a positive return on equity of 76.52%. The business had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.53 billion. During the same quarter in the prior year, the firm posted $0.40 earnings per share. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. On average, sell-side analysts anticipate that Chemours will post 0.81 earnings per share for the current year.

Insider Buying and Selling at Chemours

In other Chemours news, insider Calderon Gerardo Familiar bought 1,935 shares of Chemours stock in a transaction that occurred on Wednesday, August 12th. The stock was acquired at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the transaction, the insider directly owned 58,547 shares in the company, valued at $909,234.91. This represents a 3.42% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Denise Dignam bought 3,378 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was acquired at an average price of $14.95 per share, for a total transaction of $50,501.10. Following the completion of the purchase, the chief executive officer directly owned 339,916 shares in the company, valued at approximately $5,081,744.20. The trade was a 1.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 0.85% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of CC. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Chemours in the 2nd quarter worth approximately $34,000. Allworth Financial LP bought a new position in shares of Chemours during the 2nd quarter valued at $51,000. State of Wyoming bought a new position in shares of Chemours during the 2nd quarter valued at $67,000. Nykredit A S purchased a new position in Chemours in the 2nd quarter worth $99,000. Finally, Sterling Capital Management LLC raised its position in Chemours by 839.3% in the 3rd quarter. Sterling Capital Management LLC now owns 5,072 shares of the specialty chemicals company’s stock worth $69,000 after purchasing an additional 4,532 shares during the period. Hedge funds and other institutional investors own 76.26% of the company’s stock.

Key Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched Faizeon two-phase liquid-cooling solutions for AI data centers, which the company says can improve efficiency and reduce water use. The launch gives investors a potential growth opportunity in a fast-growing market. Article: CC Launches Faizeon Cooling Solutions to Meet AI Data Center Demand
• Neutral Sentiment: Analyst views remain mixed: Barclays maintained a Hold rating, UBS kept Neutral while trimming its price target to $15, and Truist lowered its target to $18 but retained a Buy rating. Article: Barclays Keeps Their Hold Rating on Chemours
• Negative Sentiment: Multiple law firms publicized a securities class action against Chemours, with a December 7 lead-plaintiff deadline. The lawsuit alleges the company misrepresented 2026 EBITDA guidance by not accounting for distributor pre-buying that shifted about $65 million in Opteon refrigerant sales from 2026 into 2025. The allegations have not been proven, but the case adds legal and reputational risk. Article: SueWallSt Reminds Shareholders of Lead Plaintiff Deadline
• Negative Sentiment: Recent quarterly results also provide a headwind: Chemours reported EPS of $0.21, below the $0.26 consensus and down from $0.40 a year earlier, despite revenue modestly exceeding estimates. The earnings shortfall and concerns about refrigerant demand may be contributing to investor caution.

About Chemours

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.